Detalles de la búsqueda
1.
Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma.
Int J Mol Sci;
25(2)2024 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279258
2.
Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
Hepatology;
76(2): 330-344, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897774
3.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Future Oncol;
19(34): 2277-2289, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37746835
4.
Surgical resection criteria and neoadjuvant therapies for intrahepatic cholangiocarcinoma.
Clin Adv Hematol Oncol;
21(11): 584-591, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37948594
5.
Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology.
Int J Mol Sci;
24(17)2023 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37686079
6.
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Int J Mol Sci;
24(4)2023 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36835036
7.
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Lancet Oncol;
22(10): 1468-1482, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34592180
8.
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lancet Oncol;
21(6): 808-820, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502443
9.
Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Oncologist;
25(2): 105-111, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043797
10.
Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.
Oncologist;
25(3): 197-202, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162824
11.
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Oncologist;
24(9): e930-e942, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30833489
12.
An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice.
Hepatology;
67(1): 159-170, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28718980
13.
ßII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin.
Hepatology;
61(2): 598-612, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25307947
14.
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Cancer;
121(10): 1645-53, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25641763
15.
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
J Hepatol;
63(4): 896-904, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26071796
16.
Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2.
Carcinogenesis;
35(11): 2393-403, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25096061
17.
Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC).
Int J Radiat Oncol Biol Phys;
118(2): 362-367, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37717786
18.
Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer.
J Gastrointest Cancer;
55(2): 852-861, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38347342
19.
Mechanistically based blood proteomic markers in the TGF-ß pathway stratify risk of hepatocellular cancer in patients with cirrhosis.
Genes Cancer;
15: 1-14, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38323119
20.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Lancet Gastroenterol Hepatol;
2024 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38823398